1-3 of 3
Marilyn Davis
Close
Sort by
Journal Articles

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Michele Donato, MD, Ana Aleman, MD, Donna Weber, MD, Michael Wang, MD, Muzaffer Qazilbasch, MD, Marilyn Davis, R.N., Linda Roden, MD, Floralyn Mendoza, BS, Richard Champlin, MD, Sergio Giralt, MD
Journal: Blood
Blood (2005) 106 (11): 1177.
https://doi.org/10.1182/blood.V106.11.1177.1177
Published: 2005
Journal Articles

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Sergio Giralt, MD, Ana Aleman, MD, Xin Lei, MD, Marilyn Davis, RN, Kerry Mickler, RN, Donna Weber, MD, Michael Wang, MD, Richard Champlin, MD
Journal: Blood
Blood (2004) 104 (11): 1651.
https://doi.org/10.1182/blood.V104.11.1651.1651
Published: 2004
Journal Articles

Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

Clinical Trials & Observations
Sergio Giralt, Peter F. Thall, Issa Khouri, Xuemei Wang, Ira Braunschweig, Cindy Ippolitti, David Claxton, Michele Donato, Jill Bruton, Agueda Cohen, Marilyn Davis, Borje S. Andersson, Paolo Anderlini, James Gajewski, Steven Kornblau, Michael Andreeff, Donna Przepiorka, Naoto T. Ueno, Jeff Molldrem, Richard Champlin
Journal: Blood
Blood (2001) 97 (3): 631–637.
https://doi.org/10.1182/blood.V97.3.631
Published: 2001